DNTH103

About Dianthus Therapeutics

Dianthus Therapeutics is advancing a pipeline of precision monoclonal antibodies to selectively inhibit the classical complement pathway, a key driver of autoimmune diseases. The company's lead candidate, DNTH103, is in Phase 1 clinical development for myasthenia gravis and other IgG-mediated autoimmune conditions. Dianthus aims to develop best-in-class therapies with improved convenience and safety profiles compared to existing complement inhibitors. The company leverages its expertise in complement biology to target diseases with high unmet medical need.

About Dianthus Therapeutics

Dianthus Therapeutics is advancing a pipeline of precision monoclonal antibodies to selectively inhibit the classical complement pathway, a key driver of autoimmune diseases. The company's lead candidate, DNTH103, is in Phase 1 clinical development for myasthenia gravis and other IgG-mediated autoimmune conditions. Dianthus aims to develop best-in-class therapies with improved convenience and safety profiles compared to existing complement inhibitors. The company leverages its expertise in complement biology to target diseases with high unmet medical need.

About Dianthus Therapeutics

Dianthus Therapeutics is advancing a pipeline of precision monoclonal antibodies to selectively inhibit the classical complement pathway, a key driver of autoimmune diseases. The company's lead candidate, DNTH103, is in Phase 1 clinical development for myasthenia gravis and other IgG-mediated autoimmune conditions. Dianthus aims to develop best-in-class therapies with improved convenience and safety profiles compared to existing complement inhibitors. The company leverages its expertise in complement biology to target diseases with high unmet medical need.

Therapeutic Areas

Other Generalized Myasthenia Gravis (gMG) Drugs